Quay Pharma is further expanding its operations with the purchase of a second UK laboratory and office facility.
Located at Newtech Square, close to Quay’s headquarters in Deeside Industrial Park, the new 22,500 sq ft premises will be dedicated to the company’s rapidly expanding analytical and formulation development services.
Working with small and large molecules and, uniquely, live biotherapeutics, Quay has built a strong reputation for the formulation development and clinical manufacture of unusual and difficult to handle drug substances.
The facility at Newtech Square will provide expanded capabilities in formulation development across a wider range of dosage forms and delivery techniques. In addition, new laboratories will be built to enhance the unique work that Quay does to support the growing number of companies working on therapies derived from the microbiome, which includes not only microbes but also small and large molecules that require targeted delivery throughout the body.
The transfer of Quay’s development expertise to Newtech Square will also enable the company to further develop its manufacturing capacity and capabilities at its existing site.
“We are seeing strong demand for our pharmaceutical development services, in particular our ability to provide support from the late pre-clinical stage through to First in Human supply, notably for innovative new products,” commented Maireadh Pedersen, Quay’s CEO. “Our new laboratory facilities will provide the additional space we need to invest in bringing some additional skills in house, as well as expanding the formulation services we can offer.”